EXEL — EXELIXIS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 939767 ·
Last close
$68.50
Market Cap
$16.71B
52W High
$73.69
52W Low
$39.71
ADV30
2,792,090
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 658,696,000 632,463,000 268,423,000 218,095,000 2,513,489,000 304,774,000 679,657,000
Jun 2026 628,690,000 608,033,000 248,414,000 212,050,000 2,494,234,000 281,448,000 650,472,000
Mar 2026 610,812,000 590,859,000 251,341,000 210,467,000 2,593,593,000 226,152,000 657,845,000
Dec 2025 598,663,000 572,182,000 235,910,000 244,528,000 2,844,423,000 482,488,000 683,104,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,173,057,000
Investing CF
$60,893,000
Financing CF
$-1,305,476,000
CapEx
$-28,571,000
Dividends Paid
—
Buybacks
$-1,260,907,000
EPS Diluted TTM
$3.34
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-258,802,000
Inventory
$29,871,000
Receivables
$328,466,000
ST Investments
$587,244,000
EBIT TTM
$1,004,088,000
Pretax Income TTM
$1,065,838,000
Interest Exp TTM
—
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,496,860,928
EBITDA
$1,031,900,992
Free Cash Flow
$761,998,016
Enterprise Value
$16,202,098,688
Total Cash
$892,017,984
Total Debt
$162,200,992
Shares Out
244,010,895
Trailing EPS
$3.34
Book Value
$7.50
ROE
44.3%
ROA
23.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,320,126,000 892,701,000 782,570,000 2,844,423,000 683,104,000 2,161,319,000 884,267,000
Dec 2024 2,168,701,000 689,949,000 521,267,000 2,947,690,000 703,487,000 2,244,203,000 699,971,000
Dec 2023 1,830,208,000 170,885,000 207,765,000 2,942,357,000 678,445,000 2,263,912,000 333,324,000
Dec 2022 1,611,062,000 201,484,000 182,282,000 3,071,489,000 583,062,000 2,488,427,000 362,614,000

TTM Snapshot

Revenues TTM
$2,435,920,000
NetIncome TTM
$860,623,000
OpCashFlow TTM
—
Assets (Latest)
$2,494,234,000
Forward EPS
$4.31

Max Pain — expiry 2026-12-18

max pain strike: $50.00 · spot: $68.29 · call oi: 3,938 · put oi: 13,818
Expected Move to 2026-12-18: ±$5.62 (8.24%) — implied range $62.67 – $73.92 · ATM straddle on $67.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NBIX NEUROCRINE BIOSCIENCES INC $16.79B $165.92 —
BNTX BioNTech SE $21.32B $84.86 —
TECH BIO-TECHNE Corp $11.41B $72.63 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —

News headlines (Yahoo Finance, 1h cache)

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
2026-11-16 21:52 · Yahoo
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
2026-11-13 12:25 · Yahoo
Forget clinical cash burns: Why Exelixis is up 38% since June
2026-11-12 07:15 · Yahoo
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
2026-11-11 22:12 · Yahoo
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
2026-11-11 05:14 · Yahoo
Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist
2026-11-09 16:35 · Yahoo
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
2026-11-03 21:05 · Yahoo
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
2026-11-02 13:15 · Yahoo
Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
2026-10-31 04:20 · Yahoo
Exelixis (EXEL) Q3 2026 Earnings Call Transcript
2026-10-30 15:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.